NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
Seagen Inc.
Dana-Farber Cancer Institute
Henan Cancer Hospital
Fondazione Italiana Linfomi - ETS
N.N. Petrov National Medical Research Center of Oncology
Acrotech Biopharma Inc.
Chipscreen Biosciences, Ltd.
New York Medical College